Cantor Fitzgerald Maintains Overweight on NeuroPace, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on NeuroPace (NASDAQ:NPCE) and raises the price target from $16 to $18.
March 06, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on NeuroPace and raises the price target from $16 to $18.
The upgrade in the price target by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100